scholarly journals Non-Bacterial Thrombotic Endocarditis: A Presentation of COVID-19

Author(s):  
Dilan Balata ◽  
Johan Mellergård ◽  
David Ekqvist ◽  
Jacek Baranowski ◽  
Isidro Albert Garcia ◽  
...  

The SARS-CoV-2 virus is a newly emergent pathogen first identified in Wuhan, China, and responsible for the COVID-19 global pandemic. In this case report we describe a manifestation of non-bacterial thrombotic endocarditis with continuous peripheral embolization in a COVID-19-positive patient. The patient responded well to high-dose LMWH treatment with cessation of the embolic process.

2021 ◽  
Vol 79 ◽  
pp. 164-168 ◽  
Author(s):  
Courtney Brooke Shires ◽  
Theodore Klug ◽  
Stephen Dryden ◽  
Joshua Ford

2020 ◽  
Vol 33 (03) ◽  
pp. 241-243
Author(s):  
Rajesh Kovilacar ◽  
Pankhuri Misra

Abstract Introduction The outbreak of coronavirus disease 2019 (COVID-19) has been declared as public health emergency of international concern. India is also facing this crisis with increasing number of patients being reported day by day. Here, we present a case report of COVID-19-positive patient treated with homoeopathy. Case Profile A 60-year-old female patient with fever for 4 days, cough and difficulty in breathing, headache, sore throat, loose stools and frequent urination with burning and generalised weakness for 7 days was considered for treatment in the present study. Based on the symptomatology, Arsenicum album 30 and Bryonia alba 30 were prescribed to her. Conclusion A patient of COVID-19 was successfully treated by homoeopathic medicines based on symptom similarity. Individualised homoeopathic intervention with precautionary measures can be an answer to the ongoing crisis.


2021 ◽  
pp. 239719832110043
Author(s):  
Paulina Śmigielska ◽  
Justyna Czarny ◽  
Jacek Kowalski ◽  
Aleksandra Wilkowska ◽  
Roman J. Nowicki

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.


2021 ◽  
Vol 9 (6) ◽  
Author(s):  
Shahram Ahmadian ◽  
Hadis Fathizadeh ◽  
Saeid Shabestari Khiabani ◽  
Mohammad Asgharzadeh ◽  
Hossein Samadi Kafil

2021 ◽  
pp. 194187442110043
Author(s):  
Henly Hewan ◽  
Annie Yang ◽  
Aparna Vaddiparti ◽  
Benison Keung

In late 2019, the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19, was identified. Since then many different neurological manifestations of COVID-19 have been well reported. Movement abnormalities have been rarely described. We report here a critically ill patient with COVID-19 who developed generalized myoclonus during the recovery phase of the infection. Myoclonus was associated with cyclical fevers and decreased alertness. Movements were refractory to conventional anti-epileptic therapies. There was concern that myoclonus could be part of a post-infectious immune-mediated syndrome. The patient improved fully with a 4-day course of high-dose steroids. Our experience highlights a rare, generalized myoclonus syndrome associated with COVID-19 that may be immune-mediated and is responsive to treatment.


2021 ◽  
Vol 8 ◽  
pp. 205435812110147
Author(s):  
Dimitry Buyansky ◽  
Catherine Fallaha ◽  
François Gougeon ◽  
Marie-Noëlle Pépin ◽  
Jean-François Cailhier ◽  
...  

Rationale: Immune checkpoint inhibitors are monoclonal antibodies used in the treatment of various types of cancers. The downside of using such molecules is the potential risk of developing immune-related adverse events. Factors that trigger these autoimmune side effects are yet to be elucidated. Although any organ can potentially be affected, kidney involvement is usually rare. In this case report, we describe the first known instance of a patient being treated with an inhibitor of programmed death-ligand 1 (anti-PD-L1, a checkpoint inhibitor) who develops acute tubulointerstitial nephritis after contracting the severe acute respiratory syndrome coronavirus 2. Presenting concerns of the patient: A 62-year-old patient, on immunotherapy treatment for stage 4 squamous cell carcinoma, presents to the emergency department with symptoms of lower respiratory tract infection. Severe acute kidney injury is discovered with electrolyte imbalances requiring urgent dialysis initiation. Further testing reveals that the patient has contracted the severe acute respiratory syndrome coronavirus 2. Diagnosis: A kidney biopsy was performed and was compatible with acute tubulointerstitial nephritis. Interventions: The patient was treated with high dose corticosteroid therapy followed by progressive tapering. Outcomes: Rapid and sustained normalization of kidney function was achieved after completion of the steroid course. Novel findings: We hypothesize that the viral infection along with checkpoint inhibitor use has created a proinflammatory environment which led to a loss of self-tolerance to renal parenchyma. Viruses may play a more important role in the pathogenesis of autoimmunity in this patient population than was previously thought.


PEDIATRICS ◽  
1971 ◽  
Vol 48 (2) ◽  
pp. 338-339
Author(s):  
Edward J. Feroli ◽  
Gordon W. Mella ◽  
Frank A. Pedreira ◽  
Regis T. Storch ◽  
Howard P. Gutgesell

We read with interest the recent report, "Acute Airway Obstruction in Infectious Mononucleosis."1 Dr. Gutgesell appropriately has called attention to a serious complication of a usually benign disease. He mentions brief, high-dose corticosteroid therapy, tracheotomy, nasotracheal intubation, and IPPB as potential modes of therapy. The following case report suggests an additional therapeutic modality in the management of these patients. A 4-year-old girl was admitted to a community hospital in acute respiratory distress associated with suspected infectious mononucleosis.


2016 ◽  
Vol 17 ◽  
pp. 774-781 ◽  
Author(s):  
Nina Mikirova ◽  
Ronald Hunnunghake ◽  
Ruth C. Scimeca ◽  
Charles Chinshaw ◽  
Faryal Ali ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document